Pemigatinib 4.5 MG

Phase 2Withdrawn
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreas Cancer

Conditions

Pancreas Cancer

Trial Timeline

Jun 14, 2022 → Aug 31, 2025

About Pemigatinib 4.5 MG

Pemigatinib 4.5 MG is a phase 2 stage product being developed by Incyte for Pancreas Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05216120. Target conditions include Pancreas Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05216120Phase 2Withdrawn